It can. The NHS says you may be more likely to get Crohn's if other people in your family have it. Crohn's & Colitis UK says researchers have found more than 200 gene variations that affect the risk, many involved in the immune system. Guts UK says about one in five people with Crohn's has a relative with it, but that genes alone do not decide who gets it.
CochraneSystematic reviewJun 2026Patients and professionals
An NIHR-funded Cochrane review that compares all the biologic and newer drugs for Crohn's at once, even where they were never tested against each other directly. Many, including adalimumab, risankizumab, guselkumab, upadacitinib and vedolizumab, were probably or possibly better than placebo, but the strength of evidence varied a lot. The authors say more head-to-head trials, more focus on bowel healing, and better long-term safety data are needed.
Alimentary Pharmacology & TherapeuticsDataMay 2020Patients and professionals
Using UK GP records from 2000 to 2017, this study found Crohn's became more common, rising from about 220 to 400 per 100,000 people. It predicted about 1 in 90 people in the UK would have IBD by 2025. Colitis was linked to a higher risk of bowel cancer, and both conditions to a somewhat higher risk of death than people without IBD.
The Lancet Gastroenterology & HepatologyStudyOct 2020Patients and professionals
A longer look back at the people in the LIR!C trial. It supported keyhole removal of the end of the small bowel as a real option for people with short, mainly inflamed (not narrowed) disease when standard medicines have not worked. In both groups, adding an immunosuppressant was linked to the benefit lasting longer.
One of the first 'head-to-head' trials comparing two biologics directly, in people who had never had a biologic. At one year, about 65% on ustekinumab and 61% on adalimumab were in remission, a difference too small to matter. Both worked well, so the choice between them can depend on other things such as preference and how the drug is given.